IMATIFLOW 400 MG Imatinib IP (400mg) IMATIFLOW 400 MG often marketed under the brand name Gleevec (or Glivec in some countries), is a medication used in the treatment of several types of cancer, particularly certain forms of leukemia and gastrointestinal stromal tumors (GISTs). The "IP" in "Imatinib IP" may indicate that it is a generic or unbranded version of imatinib, with "IP" standing for "International Pharmacopoeia." The standard dose of imatinib for different types of cancer may vary, but a common dose for the treatment of chronic myeloid leukemia (CML) and GIST is 400 milligrams (mg) taken orally once daily. However, the specific dosing regimen can depend on the patient's condition, disease stage, and the oncologist's recommendations. IMATIFLOW 400 MG belongs to a class of drugs known as tyrosine kinase inhibitors. It works by targeting specific proteins, such as BCR-ABL in CML and KIT in GIST, that play a critical role in the growth and proliferation of cancer cells. By inhibiting these proteins, imatinib can slow down or stop the growth of cancer cells and help manage the disease. Common side effects of imatinib may include nausea, diarrhea, fatigue, muscle cramps, and fluid retention. In some cases, more serious side effects can occur, such as low blood cell counts, liver problems, and heart-related issues. Patients should be closely monitored by their healthcare provider during treatment, and any concerning symptoms or side effects should be reported promptly. Imatinib has revolutionized the treatment of certain types of cancer and has been associated with significant improvements in patient outcomes. However, its use should be carefully managed by a healthcare professional who can assess the patient's specific condition, monitor treatment response, and adjust the dosage or treatment plan as needed. This information is provided for general knowledge, and the use of imatinib should be discussed thoroughly with a healthcare professional who can provide guidance tailored to the individual patient's diagnosis and treatment needs. Steris Healthcare Pvt. Ltd. is a Leading Pharmaceutical Company in India. Established in the year of May 2018. We have 750+ Products & 16+ Super Specialty Segments. Every week we have a new product in our portfolio. In Last 4 years we are dealing in Chronic Therapy and in 4 years we grow by 200% Annually, because we deal in high quality medicine. Steris medicine manufactures at WHO-GMP Approved Plants & We have Legal manufacturing contracts with all leading manufacturers of India. Today we have 1000+ Business Franchise Partners in PAN India. Steris's medicine supply in India's Top or Reputed Hospitals, Pharmacy, Government use or Railway use. Grow with a similar pace with the STERIS. Be first to launch like us. For further information please contact: info@sterispharma.com order now: https://www.sterisonline.com/product/imatiflow-400-133660